Drugs: musculoskeletal and joint diseases

A7.14 Identification of new inhibitors of angiogenesis in a novel 3d model of rheumatoid arthritis synovial angiogenesis
CX Maracle, P Kucharzewska, B Helder, H Olsson, SW Tas

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A61; DOI: 10.1136/annrheumdis-2016-209124.145
A2.18 Induction and characterisation of the dominant IL-10 producing B cell subset in healthy blood donors and rheumatoid arthritis patients
ZS Bankó, J Pozsgay, M Tóth, T Gáti, G Nagy, B Rojkovich, G Sármay

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A22; DOI: 10.1136/annrheumdis-2016-209124.53
A1.32 Alpha-enolase activates monocytes by CD14-dependent TLR4 signalling pathway
M Fréret, C Guillou, E Fondard, C Derambure, G Avenel, ML Golinski, M Verdet, O Boyer, F Caillot, P Musette, T Lequerré, O Vittecoq

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A14; DOI: 10.1136/annrheumdis-2016-209124.32
A2.34 Anti-inflammatory effects of vitamin D are reduced in T-cells from the inflamed joints of rheumatoid arthritis patients
LE Jeffery, P Henley, M Hewison, A Filer, DM Sansom, K Raza

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A29; DOI: 10.1136/annrheumdis-2016-209124.69
A2.19 IL-17A-low CCR6+ TH cell populations of patients with rheumatoid arthritis are pathogenic, multidrug resistant and associated with dmard and glucocorticoid treatment response
JP van Hamburg, SMJ Paulissen, N Davelaar, JMW Hazes, E Lubberts

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A22-A23; DOI: 10.1136/annrheumdis-2016-209124.54
A1.27 MPGES-1 deletion increases prostacyclin and evades the elevated systemic ADMA associated with COX-2 inhibitors: relevance to cardiovascular safety of mpges-1 inhibitors
J Raouf, NS Kirkby, B Ahmetaj-Shala, B Liu, SI Mazi, M Korotkova, Y Zhou, JA Mitchell, PJ Jakobsson

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A11-A12; DOI: 10.1136/annrheumdis-2016-209124.27
A2.25 Vitamin D induces a TR1-like phenotype in human CCR6⁺T cells and promotes their migration to an inflammatory environment
W Dankers, JP van Hamburg, N Davelaar, PS Asmawidjaja, K Wen, W Razawy, M Molendijk, JPTM Van Leeuwen, EM Colin, E Lubberts

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A25; DOI: 10.1136/annrheumdis-2016-209124.60
A1.29 Normal and rheumatoid arthritis neutrophil extracellular TRAPS are both pro- and anti-inflammatory via mechanisms involving the C1Q complement protein but independently of ACPA, ll-37 or the inflammasome
M Ribon, S Seninet, K Matyja, M Sebbag, C Clavel, J Mussard, G Serre, MC Boissier, P Decker

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A12-A13; DOI: 10.1136/annrheumdis-2016-209124.29
A1.11 A20 controls activation of STAT1, but has no effect on STAT3: Implications for development of enthesitis
K De Wilde, A Martens, J Coudenys, K Debusschere, E Verheugen, F Windels, R Beyaert, G van Loo, D Elewaut

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A5; DOI: 10.1136/annrheumdis-2016-209124.11
A1.17 Podoplanin and its ligand CLEC-2 restrain synovial inflammation
GE Desanti, AJ Naylor, L Navarro Núñez, AN Saghir, DL Hardie, SP Watson, CD Buckley

Annals of the Rheumatic Diseases Feb 2016, 75 (Suppl 1) A7; DOI: 10.1136/annrheumdis-2016-209124.17

Main menu

Drugs: musculoskeletal and joint diseases

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Drugs: musculoskeletal and joint diseases

Pages